Author Page for Davide Massa

Immunotherapy in Rare Ovarian Cancer: A Case of Durable Response in Advanced Platinum-Resistant Squamous Cell Carcinoma

Number of pages: 13 Posted: 12 Mar 2025

Davide Massa, Lara Alessandrini, Angela Guerriero, Roberto Tozzi, Matteo Marchetti, Carlo Saccardi, Giulia Spagnol, Valentina Guarneri and Giulia Tasca

affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Padua, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN

Downloads 60 (980,173)

Abstract:

2.

Development of a machine learning model to guide further metastatic biopsy decision in patients with HER2-0 status on both primary breast cancer and first biopsied metastatic site: who should undergo a repeated biopsy to detect HER2-low gain?

Downloads 32 (1,318,317)

2

Development of a machine learning model to guide further metastatic biopsy decision in patients with HER2-0 status on both primary breast cancer and first biopsied metastatic site: who should undergo a repeated biopsy to detect HER2-low gain?

Number of pages: 17 Posted: 12 Jan 2026

affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, London School of Hygiene & Tropical Medicine - Cancer Survival Group, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Sapienza University of Rome, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Padua - Department of Medicine, Università di Padova - Dipartimento di Scienze Chirurgiche and affiliation not provided to SSRN

Downloads 20 (1,513,226)

Abstract:

Development of a machine learning model to guide further metastatic biopsy decision in patients with HER2-0 status on both primary breast cancer and first biopsied metastatic site: who should undergo a repeated biopsy to detect HER2-low gain?

Number of pages: 17 Posted: 14 Jan 2026

affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, London School of Hygiene & Tropical Medicine - Cancer Survival Group, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Sapienza University of Rome, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Padua - Department of Medicine, Università di Padova - Dipartimento di Scienze Chirurgiche and affiliation not provided to SSRN

Downloads 12 (1,598,105)

Davide Massa

affiliation not provided to SSRN

2

92

0

Scholarly Papers (2)

Immunotherapy in Rare Ovarian Cancer: A Case of Durable Response in Advanced Platinum-Resistant Squamous Cell Carcinoma

Abstract:

Development of a machine learning model to guide further metastatic biopsy decision in patients with HER2-0 status on both primary breast cancer and first biopsied metastatic site: who should undergo a repeated biopsy to detect HER2-low gain?

Development of a machine learning model to guide further metastatic biopsy decision in patients with HER2-0 status on both primary breast cancer and first biopsied metastatic site: who should undergo a repeated biopsy to detect HER2-low gain?

Abstract:

Development of a machine learning model to guide further metastatic biopsy decision in patients with HER2-0 status on both primary breast cancer and first biopsied metastatic site: who should undergo a repeated biopsy to detect HER2-low gain?

Abstract: